Author:
Surasi Devaki Shilpa,Eiber Matthias,Maurer Tobias,Preston Mark A.,Helfand Brian T.,Josephson David,Tewari Ashutosh K.,Somford Diederik M.,Rais-Bahrami Soroush,Koontz Bridget F.,Bostrom Peter J.,Chau Albert,Davis Phillip,Schuster David M.,Chapin Brian F.,Allaf Mohamad,Andriole Gerald,Avery Ryan J.,Avril Norbert,Barker Helen,Belkoff Laurence,Budäus Lars,Cher Michael L.,Chisholm Diane,Covington Matthew F.,Cox Ian,Ferrandino Michael,Fleming Mark T.,Franceschi Dinko,Gardiner Peter,Gartrell Benjamin,Gauden David,Hasa Ergela,Hermsen Rick,Horn Thomas,Iranpour Pooya,Jacene Heather,Jayaratna Isuru,Joshi Shreyas S.,Kay Matthew,Kostakoglu Lale,Kuo Phillip,Lavely William,Lokuta Mary,Lowentritt Benjamin,Miller Matthew P.,Nix Jeffrey W.,Ogan Kenneth,Penny Ross,Piert Morand,Purysko Andrei,Ravizzini Gregory,Saltzstein Daniel,Savir-Baruch Bital,Siegel Barry A.,Steuber Thomas,Twardowski Przemyslaw,Uchio Edward,Ulaner Gary A.,Wixom Jenna M.,Yoo Don,Zukotynski Katherine
Reference33 articles.
1. Union for International Cancer Control. TNM classification of malignant tumours. 2022. https://www.uicc.org/resources/tnm.
2. NCCN. NCCN clinical practice guidelines in oncology: prostate cancer. Version 1.2022. 2021. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
3. Application of bone scans for prostate cancer staging: which guideline shows better result?;Chong;Can Urol Assoc J,2014
4. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis;Hovels;Clin Radiol,2008
5. FDA. FDA approves second PSMA-targeted PET imaging drug for men with prostate cancer. 2021. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer.